Pallas Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pallas Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,942	Closed	-$520K	–	947
2025 Q1	$520K	Buy	3,942 +760	+24%	+$94.7K	0.02%	451
2024 Q4	$266K	Buy	3,182 +192	+6%	+$15.8K	0.01%	493
2024 Q3	$226K	Sell	2,990 -1,130	-27%	-$84.9K	0.01%	547
2024 Q2	$309K	Buy	+4,120	New	+$286K	0.01%	403

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pallas Capital Advisors's ITCI Position: Q2 2025 in Review

Pallas Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,942 shares — an estimated $520K sold.

Pallas Capital Advisors first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $520K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Pallas Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Pallas Capital Advisors sold 3,942 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $520K.
Pallas Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Pallas Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $520K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Pallas Capital Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.